• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Biogen bolsters pipeline again with Alectos deal

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 07, 2022 at 10:02: AM
via Biogen has added a preclinical-stage drug candidate for Parkinson’s disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side-lined Alzheimer’s therapy Aduhelm.

article source
 




Top Bottom
Back
Quote